The neoplastic B-cell derived Hodgkin and ReedSternberg cells (HRS) in classical Hodgkin's lymphoma (cHL) undergo a substantial loss of B-cell identity. It has been suggested that epigenetic mechanisms such as DNA methylation are involved in this cHL-associated reprogramming. 1 In a recent array-based DNA-methylation study using 27K methylation arrays, we identified 209 protein encoding genes hypermethylated in cHL but not in other germinal center derived B-cell lymphomas as compared to normal B cells. These genes, exclusively hypermethylated in cHL, are enriched for functions such as regulation of B-cell or T-cell activation.
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DNA methylation is an epigenetic mechanism associated with gene inactivation that can not only cause gene silencing de novo, but can also be acquired as a consequence of upstream gene downregulation 3 and in cHL, a loss of a master transcription factor could lead to the methylation of genes involved in B-cell identity. We, therefore, tested the 209 genes hypermethylated exclusively in cHL that we had identified in our previous study for transcription factor binding sites. 2 The most significant enrichment was seen for the transcription factors EBF1/OLF1 and E2A (E12/E47) which have both been previously shown to be involved in B-cell regulation and to be deregulated in cHL (Table 1) . [4] [5] Binding sites for another key B-cell transcription factor, ETS1, ranked third among the group of genes hypermethylated exclusively in cHL. This led us to analyze the ETS1 gene for mutations, copy number alterations and expression both on mRNA and protein level in cHL cell lines and primary biopsies.
We collected published gene expression microarray data for the L428, HDLM2, KMH2 and L1236 cHL cell lines as compared to normal B-cell entities (5 centroblasts, 5 centrocytes, 5 naive B cells, 5 memory B cells) 6 and analyzed the expression of the transcription factors that were identified (Table 1) . ETS1 was strongly downregulated with a 7.23-fold reduced expression in cHL cell lines (t-test P<0.001) ( Figure 1A) . This prompted us to analyze whether the observed downregulation of ETS1 is also present in primary cHL and results in reduced protein expression. In reactive tonsils, the nuclei of germinal center, mantle zone and parafollicular cells expressed the ETS1 protein as shown by immunohistochemistry whereas the squamous epithelium remained negative. In 8 of 17 (47%) evaluable cHL, the HRS cells were completely devoid of ETS1 protein expression whereas expression was confirmed in the nuclei of bystander cells ( Figure 1B ). In addition, 7 of 17 (41%) cHL presented a heterogeneous pattern of expression with both positive and negative HRS cells for ETS1 protein. Only in 2 of 17 (12%) cases did all HRS cells retain expression of ETS1 on a protein level.
As ETS1 was not among the hypermethylated genes in cHL and, therefore, is itself not silenced by gene methylation, 2 we performed mutation screening for the entire coding sequence of this gene in 7 cHL cell lines. In the L540 cell line, an 11 bp heterozygous intronic deletion (NM_001143820.1:c.1123+5_1123+15delGCGCCCTCC CG; chr11:128,350,071-128,350,081; hg19) was identified. This deletion cannot be attributed to a known copy number variation as only a single nucleotide polymorphism (SNP) (chr11:128350071) is annotated for this location according to the University of California Santa Cruz (UCSC) Genome hg19 (http://genome.ucsc.edu) and the 1000 Genome (http://browser.1000genomes.org) databases. As the deletion is located 5 bp from the 3' splicing site of exon 8, we used RT-PCR for exons 6-10 to detect potential changes in splicing but this mutation was not seen to exert any effect. These findings suggest that the deletion identified does not affect ETS1 protein functionality. Neither mutations in the coding exons nor the adjacent intronic sites were identified in any other cell line.
Next, we performed a copy number analysis by fluorescence in situ hybridization (FISH) and identified heterozygous deletions of the ETS1 locus in 2 of 7 (29%) cHL cell lines, KMH2 and SUPHD1. Expression of the ETS1 transcription factor in KMH2 is strongly down-regulated in the gene expression microarray data. 6 Interestingly, for SUPHD1, that was not included in this microarray study, 1612 haematologica | 2012; 97 (10) LETTERS TO THE EDITOR Recently, non-synonymous mutations of ETS1 7 and copy number gains 8 probably resulting in activation of the gene were identified in diffuse large B-cell lymphomas. In contrast, the heterozygous deletions of the ETS1 locus in HRS cells reported here can result in haploinsufficiency causing reduced expression of ETS1 protein and, consequently, of its target genes. Haploinsufficiency has already been described in hematologic malignancies; the PAX5 transcription factor is lost in approximately 30% of cases of acute lymphoblastic leukemia. 9 It has previously been shown that ETS1 functions either as transcriptional activator or repressor, and it was reported to have oncogenic potential.
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Furthermore, several authors reported the involvement of ETS1 in hematopoiesis, including impaired B-cell development in mice with defective ETS1.
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According to these data, we propose a model in which the epigenetic downregulation of B-cell specific genes in cHL might be mediated by primary deregulation of upstream regulators of the B-cell program. We suggest ETS1 is a player in this process and recurrent deletions and loss of expression of this transcription factor in cHL might contribute to the escape potential and survival of HRS cells. In colour only online 
Lack and/or aberrant localization of major histocompatibility class II (MHCII) protein in plasmablastic lymphoma
Plasmablastic lymphoma (PBL) was recently reclassified as a distinct entity of mature B-cell neoplasm.
1,2 However, the diagnostic distinction of PBL from diffuse large B-cell lymphoma (DLBCL) is still a common problem due to the lack of biomarkers for PBL.
3 Recently, Montes-Moreno et al. published a study in Hematologica describing several PBL phenotypes that help to differentiate PBL from DLBCL. 4 A major characteristic of these PBL cases (full and variant plasmablastic phenotypes) which distinguished them from conventional DLBCL was PRDM1/Blimp1 positivity. 4 The authors further demonstrated that the rare acquisition of a partial, Blimp1 positive, plasmablastic phenotype in a minority of DLBCL cases was associated with poorer patient outcome. Letters to the Editor 
